Florina-Delia Andriesi-Rusu, Ana-Maria Trofin, Irene Cianga-Spiridon, Nutu Vlad, Alin Vasilescu, Eugen Târcoveanu and Cristian Lupașcu
Background: Pancreatic ductal adenocarcinoma is one of the most aggressive neoplasms, with a poor prognostic and overall survival, most of the patients (over 80%) being diagnosed in advanced stages of the disease, either with distant metastasis or with the locally unresectable tumor. The Ki-67 antigen is a nuclear antigen expressed in all cellular phases (except for the G0 phase) and a high Ki-67 index can be correlated with a recurrence rate of tumor and survival.
Aim: The aim of our study was to demonstrate if the Ki-67 index can be used as a negative prognostic factor for survival.
Methods: We reviewed retrospectively all patients with pancreatic ductal adenocarcinoma (confirmed histologically) and were selected only those with resectable tumors (19.5%). For these patients, immunoreactivity for Ki-67 was evaluated according to the percentage of positive tumor nuclei. The survival was calculated from the data of surgery to a patient’s death.
Results: 19.5% of patients were diagnosed with surgically resectable tumors, with a mean tumor’s size of 3.3 cm. The overall survival rate at 2 years was 21.15%. The patients with a Ki-67 index over 80% had a significantly lower average survival than the other patients.
Conclusions: The immunohistochemistry staining for Ki-67 can be applied as a prognostic marker for survival in resectable ductal pancreatic adenocarcinoma.
Share this article
Copyright: This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
To cite this article:
Jan 01, 1970
Accepted Date: Jan 01, 1970
Published Date: Jan 01, 1970